Form 4: 2seventy bio, Inc. Director Disposes of Shares in Merger with Bristol-Myers Squibb

Director Sarah JS Glickman reports the disposal of shares and stock options in 2seventy bio, Inc. following the completion of a merger with Bristol-Myers Squibb Company.

Summary

• Sarah JS Glickman, a director of 2seventy bio, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The filing reports transactions related to the merger between 2seventy bio, Inc. and Bristol-Myers Squibb Company, which became effective on May 13, 2025.
• Glickman disposed of 12,050 shares of common stock and 15,602 restricted stock units (RSUs) as part of the merger agreement.
• Each share of common stock and RSU was converted into the right to receive $5.00 in cash.
• Glickman's stock options, with an exercise price of $3.93, were also cancelled and converted into the right to receive the excess of the merger consideration over the exercise price.
• The director now holds zero shares of common stock and zero stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides a cash payout to shareholders, but it also means the end of 2seventy bio as an independent entity. The score reflects the completion of a transaction that provides immediate value to shareholders.

Positives

• Shareholders received $5.00 per share in cash as part of the merger agreement.
• RSUs became fully vested and were converted into cash.
• Stock options with an exercise price below the merger consideration were converted into cash.

Negatives

• Glickman no longer holds any shares or stock options in 2seventy bio, Inc.

Risks

• The company is now a wholly-owned subsidiary of Bristol-Myers Squibb, meaning minority shareholders no longer have a stake in the company's future.

Future Outlook

2seventy bio, Inc. will continue as the surviving corporation and a wholly-owned subsidiary of Bristol-Myers Squibb Company.

Industry Context

This merger reflects a trend in the biotechnology industry where larger pharmaceutical companies acquire smaller, innovative firms to expand their pipelines and capabilities.

Comparison to Industry Standards

• Acquisition premiums in the biotech industry typically range from 30% to 60% above the target's pre-announcement stock price, depending on the strategic value and potential synergies.
• Comparable acquisitions include Gilead Sciences' acquisition of Kite Pharma and Roche's acquisition of Spark Therapeutics, both aimed at bolstering their cell and gene therapy portfolios.
• The $5.00 per share merger consideration should be compared to the trading multiples of other biotech companies with similar revenue and growth prospects to assess its fairness.

Stakeholder Impact

• Shareholders received cash for their shares.
• Employees of 2seventy bio are now employees of Bristol-Myers Squibb.
• The merger may impact the company's relationships with its suppliers and customers.

Key Dates

Keywords

Merger, 2seventy bio, Bristol-Myers Squibb, Form 4, Director, Glickman, Beneficial Ownership, Disposition, Stock Options, RSUs